Sain Medicaments Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 30-11-2024
- Paid Up Capital ₹ 1.00 Cr
as on 30-11-2024
- Company Age 41 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 10.90 Cr
as on 30-11-2024
- Satisfied Charges ₹ 0.85 M
as on 30-11-2024
- Revenue -1.16%
(FY 2024)
- Profit -2.95%
(FY 2024)
- Ebitda 82.48%
(FY 2024)
- Net Worth 1.33%
(FY 2024)
- Total Assets -5.90%
(FY 2024)
About Sain Medicaments
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹10.90 Cr. The company has closed loans amounting to ₹0.85 M, as per Ministry of Corporate Affairs (MCA) records.
Girish Gupta, Kumud Agarwal, Sumit Agarwal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230TG1983PTC004015
- Company No.
004015
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jun 1983
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Sain Medicaments Private Limited offer?
Sain Medicaments Private Limited offers a wide range of products and services, including Cleaning Liquids & Wipes, Surface Cleaner, Cardiovascular Drugs & Medication, Diabetes Medicine, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Anti Infective Drugs & Medicines, HIV Drugs, Antiviral Drugs, Pain Relief Drugs & Pharmaceuticals.
Who are the key members and board of directors at Sain Medicaments?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Girish Gupta  | Managing Director | 30-Jun-1983 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sumit Agarwal | Director | 01-Sep-2009 | Current |
| Manmeet Agarwal | Director | 01-Jul-2011 | Current |
| Kumud Agarwal | Director | 01-Jan-1985 | Current |
Financial Performance of Sain Medicaments.
Sain Medicaments Private Limited, for the financial year ended 2024, experienced Minor drop in revenue, with a 1.16% decrease. The company also saw a slight decrease in profitability, with a 2.95% decrease in profit. The company's net worth moved up by a moderate rise of 1.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sain Medicaments?
In 2024, Sain Medicaments had a promoter holding of 87.61% and a public holding of 12.39%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sain Biocare Private LimitedActive 10 months 14 daysSumit Agarwal and Manmeet Agarwal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 08 Sep 2023 | ₹3.40 M | Open |
Hdfc Bank Limited Creation Date: 19 May 2018 | ₹10.56 Cr | Open |
Syndicate Bank Creation Date: 17 Jun 1996 | ₹0.25 M | Satisfied |
How Many Employees Work at Sain Medicaments?
Sain Medicaments has a workforce of 23 employees as of Nov 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sain Medicaments, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sain Medicaments's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
